<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: There are few safe antiarrhythmics for <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Whereas ranolazine is a promising late <z:chebi fb="0" ids="33167">INa</z:chebi> blocker with antiarrhythmic effects, and devoid of pro-arrhythmic properties, there are no direct comparisons between ranolazine and other antiarrhythmic agents in an <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion setting </plain></SENT>
<SENT sid="2" pm="."><plain>HYPOTHESIS AND METHODS: To determine whether ranolazine was as effective as sotalol and <z:chebi fb="0" ids="6456">lidocaine</z:chebi> to reduce <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion-induced <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, anesthetized rats were subjected to 5 minutes of proximal left coronary <z:mp ids='MP_0006134'>artery occlusion</z:mp> plus 5 minutes of reperfusion, which causes severe <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>At 21 minutes prior to <z:e sem="disease" ids="C0151814" disease_type="Disease or Syndrome" abbrv="">coronary occlusion</z:e>, rats (n = 20 per group) were randomized to receive either sotalol (intravenous [IV] bolus 5 mg/kg, 10 mg/kg per hour infusion), <z:chebi fb="0" ids="6456">lidocaine</z:chebi> (IV bolus 2.5 mg/kg, 2.5 mg/kg/hr infusion), ranolazine (IV bolus 3.3 mg/kg, 3.2 mg/kg per hour infusion), or saline (control) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The incidence of <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in the sotalol (S), <z:chebi fb="0" ids="6456">lidocaine</z:chebi> (L), ranolazine (R), and control (C) groups was 7/20, 10/20, 9/20, and 16/20, respectively (P = .01 S vs C, P = .10 L vs C, and P = .048 R vs C) </plain></SENT>
<SENT sid="5" pm="."><plain>Duration of <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT) episodes was reduced from 15.5 seconds (mean) in C to 1.3 seconds in S, 1.4 sec in L and 0.09 sec in R (P &lt; .05 for S vs C and R vs C by Wilcoxon test) </plain></SENT>
<SENT sid="6" pm="."><plain>The number of rats with any (â‰¥ 10 seconds) sustained VT was 3 in C versus 1, 0, and 0 in the S, L, and R groups, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Two rats in C had reversible <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> versus 0 in the S, L, and R groups </plain></SENT>
<SENT sid="8" pm="."><plain>The number of <z:mp ids='MP_0009732'>ventricular premature beats</z:mp> (<z:mp ids='MP_0009732'>VPBs</z:mp>) per rat was 10.9 in C, 2.3 in S, 4.9 in L, and 5.7 in R (P &lt; .05 for S, L, or R vs C) </plain></SENT>
<SENT sid="9" pm="."><plain>P = NS for R versus L or S for <z:hpo ids='HP_0000001'>all</z:hpo> analyses </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: In this first head-to-head comparison of R vs other antiarrhythmic agents at therapeutic doses in an <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion model, ranolazine (which lacks pro-arrhythmic effects) was as effective as either sotalol or <z:chebi fb="0" ids="6456">lidocaine</z:chebi> to reduce reperfusion-induced <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
</text></document>